Article
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
The oncologist - 1 Oct 2015
Heigener David F, Schumann Christian, Sebastian Martin, Sadjadian Parvis, Stehle Ingo, Märten Angela, Lüers Anne, Griesinger Frank, Scheffler Matthias
Abstract excerpt
BACKGROUND: Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. Efficacy of afatinib in EGFR tyrosine kinase inhibitor-naïve (TKI-naïve) patients with uncommon EGFR mutations (other than exon 19 deletions or exon 21 point mutations) has been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.